Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 21

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Toxic epidermal necrolysis

Recruiting

Treatment with Mesenchymal Stromal Cells for Adults with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS-TEN) Affecting More Than 10% of Body Surface

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Allogeneic Adipose-Derived Mesenchymal Stromal Cells, Ex-Vivo Expanded
  • Sponsor:Assistance Publique Hopitaux De Paris

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dnth103
  • Sponsor:Dianthus Therapeutics Inc.

Eosinophilic granulomatosis with polyangiitis

Recruiting

Study on the Effects of Mepolizumab on Nasal Health and Immune Response in Patients with Eosinophilic Granulomatosis with Polyangiitis (eGPA)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Mepolizumab
  • Sponsor:Universitair Medisch Centrum Groningen

Multiple sclerosis

Recruiting

Study of [18F]-DPA-714 PET imaging to assess neuroinflammation in multiple sclerosis patients compared to healthy controls

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
  • Sponsor:Assistance Publique Hopitaux De Paris

Dermatitis allergic

Recruiting

Study on the Safety and Effectiveness of Metal Panel Allergens for Patients with Allergic Contact Dermatitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:ZINC CHLORIDE
  • Sponsor:Smarthealth Inc.

Crohn's disease

Recruiting

Study on Fecal Microbiota Transplantation for Crohn's Disease Patients in Remission After Stopping Anti-TNF Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Placebo
  • Sponsor:Assistance Publique Hopitaux De Paris

Crohn's disease

Recruiting

Study on Using Ultrasound with Perflubutane and Laxative for Detecting Crohn's Disease in Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Macrogol 3350
  • Sponsor:Helse Bergen HF

Follicular lymphoma+7

Recruiting

Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Atezolizumab
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Interstitial lung disease

Recruiting

Study of Rituximab versus Placebo to Improve Lung Function in Patients with Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Oslo University Hospital HF

IgA nephropathy

Recruiting

Study on Ravulizumab for Children with IgA Nephropathy (Ages 2-17)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Graves' disease

Recruiting

Study on the Effectiveness and Safety of IMVT-1402 for Adults with Graves' Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:IMEROPRUBART
  • Sponsor:Immunovant Sciences GmbH

Idiopathic pulmonary fibrosis+1

Recruiting

Long-Term Safety Study of Inhaled Pirfenidone for Patients with Progressive or Idiopathic Pulmonary Fibrosis

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.